Pivmecillinam

Identification

Summary

Pivmecillinam is a prodrug of the beta lactam antibiotic mecillinam, indicated for the treatment of uncomplicated urinary tract infections (UTIs).

Generic Name
Pivmecillinam
DrugBank Accession Number
DB01605
Background

Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. [PubChem]

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 439.569
Monoisotopic: 439.214091871
Chemical Formula
C21H33N3O5S
Synonyms
  • Amdinocillin pivoxil
  • amdinocillin, pivaloyloxymethyl ester
  • Pivmecilinamo
  • Pivmecillinam
  • Pivmecillinamum
External IDs
  • RO 10-9071

Pharmacology

Indication

Used to treat infections due to mecillinam-sensitive organisms such as urinary tract infections, salmonellosis and typhoid fever.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofUrinary tract infection caused by e. coli••••••••••••••••••
Treatment ofUrinary tract infection caused by enterobacteria••••••••••••••••••
Treatment ofUrinary tract infection caused by klebsiella••••••••••••••••••
Treatment ofUrinary tract infection caused by proteus••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Pivmecillinam is a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin.

Mechanism of action

Pivmecillinam interferes with the biosynthesis of the bacterial cell wall however its activity is slightly different from that of other penicillins and cephalosporins

TargetActionsOrganism
APenicillin-binding protein 1A
inhibitor
Clostridium perfringens (strain 13 / Type A)
Absorption

Well absorbed following oral administration.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcemetacinAcemetacin may decrease the excretion rate of Pivmecillinam which could result in a higher serum level.
AcenocoumarolPivmecillinam may increase the anticoagulant activities of Acenocoumarol.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Pivmecillinam is combined with Ambroxol.
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Pivmecillinam.
ArticaineThe risk or severity of methemoglobinemia can be increased when Pivmecillinam is combined with Articaine.
Food Interactions
  • Take with or without food. The absorption is unaffected by food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Pivmecillinam hydrochloride48FX7N21H232887-03-9UHPXMYLONAGUPC-WKLLBTDKSA-N
International/Other Brands
Coactabs
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SelexidTablet200 mgOralKaro Healthcare AbNot applicableNot applicableCanada flag
SelexidTablet400 mgOralKaro Healthcare AbNot applicableNot applicableCanada flag
Selexid Tab 185mgTablet185 mgOralLeo Pharma1985-12-312012-08-02Canada flag

Categories

ATC Codes
J01CR50 — Combinations of penicillinsJ01CA08 — Pivmecillinam
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid esters
Alternative Parents
Penams / Acylals / Azepanes / Dicarboxylic acids and derivatives / Thiazolidines / Tertiary carboxylic acid amides / Azetidines / Formamidines / Dialkylthioethers / Carboximidamides
show 9 more
Substituents
Acetal / Acylal / Aliphatic heteropolycyclic compound / Alpha-amino acid ester / Amidine / Azacycle / Azepane / Azetidine / Beta-lactam / Carbonyl group
show 23 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
penicillanic acid ester, penicillin (CHEBI:51210)
Affected organisms
  • Enteric bacteria and other eubacteria

Chemical Identifiers

UNII
1WAM1OQ30B
CAS number
32886-97-8
InChI Key
NPGNOVNWUSPMDP-HLLBOEOZSA-N
InChI
InChI=1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/t14-,15+,17-/m1/s1
IUPAC Name
[(2S,5R,6R)-6-{[(azepan-1-yl)methylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carbonyloxy]methyl 2,2-dimethylpropanoate
SMILES
[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1

References

General References
  1. Sjovall J, Huitfeldt B, Magni L, Nord CE: Effect of beta-lactam prodrugs on human intestinal microflora. Scand J Infect Dis Suppl. 1986;49:73-84. [Article]
  2. Graninger W: Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. [Article]
  3. Authors unspecified: Pivmecillinam (selexid). Drug Ther Bull. 1978 Dec 22;16(26):103-4. [Article]
Human Metabolome Database
HMDB0015543
KEGG Drug
D02889
PubChem Compound
115163
PubChem Substance
46506880
ChemSpider
16735658
RxNav
627
ChEBI
51210
ChEMBL
CHEMBL1616433
Therapeutic Targets Database
DAP001174
PharmGKB
PA164750167
Wikipedia
Pivmecillinam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionComplications / Infection / Prostate Cancer1
4CompletedTreatmentPyelonephritis / Urinary Tract Infection1
4RecruitingTreatmentUrinary Tract Infection1
3CompletedTreatmentUncomplicated Urinary Tract Infections1
3RecruitingTreatmentAntibiotic Resistant Infection / Bacteremia / Urinary Tract Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Granule
TabletOral
TabletOral200 mg
TabletOral400 mg
Tablet, film coatedOral200 mg
Tablet, film coatedOral
TabletOral185 mg
Tablet, film coatedOral400 MG
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)119 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0526 mg/mLALOGPS
logP3.23ALOGPS
logP2.91Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.66Chemaxon
pKa (Strongest Basic)7.91Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area88.51 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity113.03 m3·mol-1Chemaxon
Polarizability47.68 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.962
Blood Brain Barrier-0.9659
Caco-2 permeable-0.5577
P-glycoprotein substrateSubstrate0.7368
P-glycoprotein inhibitor IInhibitor0.603
P-glycoprotein inhibitor IINon-inhibitor0.5211
Renal organic cation transporterNon-inhibitor0.7087
CYP450 2C9 substrateNon-substrate0.8243
CYP450 2D6 substrateNon-substrate0.8069
CYP450 3A4 substrateSubstrate0.5997
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9396
Ames testNon AMES toxic0.6178
CarcinogenicityNon-carcinogens0.8141
BiodegradationNot ready biodegradable0.5067
Rat acute toxicity2.1874 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9925
hERG inhibition (predictor II)Non-inhibitor0.6363
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0a4i-9012000000-ea9d35d8c75e4246ab91
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0140900000-797f11e6106d37dd79f2
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udr-0207900000-1b06459a25762bdbc7f7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-6519300000-9775283680d7eedc9b7b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0ukl-9886200000-928d463fb23511f7689b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0079-9672100000-a1070472a54556cf2a5b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-05p9-1922000000-f615ec325d4d972da86c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-202.0340705
predicted
DarkChem Lite v0.1.0
[M-H]-209.16405
predicted
DeepCCS 1.0 (2019)
[M+H]+203.0350705
predicted
DarkChem Lite v0.1.0
[M+H]+211.51758
predicted
DeepCCS 1.0 (2019)
[M+Na]+202.5000705
predicted
DarkChem Lite v0.1.0
[M+Na]+217.43091
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Clostridium perfringens (strain 13 / Type A)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring glycosyl groups
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
pbpA
Uniprot ID
Q8XJ01
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
75176.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Graninger W: Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. [Article]

Drug created at August 29, 2007 18:48 / Updated at May 25, 2024 22:42